

triCalculate IM Analytics


Firms coming into scope for uncleared margin rules for 2020 and 2021 are faced with a variety of operational challenges around the calculation and exchange of initial margin (IM). Now, triCalculate can help you prepare and make more informed IM business decisions with comprehensive IM analytics.

Today's Planning, Tomorrow's Success

triCalculate IM Analytics provides crucial insight into your options for IM calculation, helps identify and prioritize in-scope counterparties and aids decisions to reduce future IM costs.

Proven, Comprehensive, and Customizable

triCalculate's IM Analytics are customizable to your requirements and can be provided on a periodical or ad-hoc basis. With no upfront fees, all that's required to get started is a simple trade file in any format, representing a real or hypothetical portfolio.



With triCalculate IM Analytics You Can Determine:

SIMM™ vs. Schedule

You must decide to use either the schedule or the ISDA Standard Initial Margin Model (SIMM™) calculation method as it needs to be pre-agreed with your counterparties. triCalculate supports both methodologies and can help in the SIMM™ vs. schedule decision-making process with analytics on the effects of each methodology on IM costs.

SIMM™ Sample

party_id	counterparty_id	site	risk_class	simmtot	type	bucket	trunc_count	ptot	ptot_gm	secured_im
DEMO	TEST COUNTERPARTY			13	4,988,055,924	4,853,965,789				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	9	4,175,607,489	4,509,875,243				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	4	511,254,995	511,254,995				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	2	128,754,147	128,754,147				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	2	422,254,187	422,254,187				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	4	65,732,246	0				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	2	2,762,246	1,763,168				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	2	9,876,182	9,876,182				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	9	3,999,102,248	3,999,102,248				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	2	3,997,103,817	3,997,103,817				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	2	105,188,572	105,188,572				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	13	354,000,346	354,000,346				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	13	354,000,346	354,000,346				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	13	490,780,945	490,780,945				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	7	200,143,189	200,143,189				
DEMO	TEST COUNTERPARTY	Rate/FX	FX	2	42,152,690	42,152,690				

Schedule Sample

party_id	counterparty_id	Asset class	IM requirement (% of notional exposure)	trade_count	Gross_IM	Party Mtm	NetReplacementCost Pledgor Party	GrossReplacementCost Pledgor Party	NetReplacementCost Secured Party	GrossReplacementCost Secured Party	pledgor_im	secured_im	
DEMO	TEST COUNTERPARTY	Credit: 0-2 year duration		2	0	0							
DEMO	TEST COUNTERPARTY	Credit: 2-5 year duration		5	0	0							
DEMO	TEST COUNTERPARTY	Credit: 5+ year duration		10	0	0							
DEMO	TEST COUNTERPARTY	Commodity		15	0	0							
DEMO	TEST COUNTERPARTY	Equity		15	0	0							
DEMO	TEST COUNTERPARTY	Foreign Exchange		6	8	3,155,478,000							
DEMO	TEST COUNTERPARTY	Interest Rate: 0-2 year duration		1	2	504,250,000							
DEMO	TEST COUNTERPARTY	Interest Rate: 2-5 year duration		2	3	852,638,000							
DEMO	TEST COUNTERPARTY	Interest rate: 5+ year duration		4	0	0							
DEMO	TEST COUNTERPARTY	Other		15	0	0							
DEMO	TEST COUNTERPARTY				13	4,512,366,000	735,534	0	925,000	735,534	899,500	1,804,946,400	4,018,842,084

Sample Your Future IM Costs

It's essential to understand what your IM cost will be triCalculate IM Analytics allows you to identify a suitable portfolio for your first week's, month's, and year's worth of trading and to simulate your IM cost across all eligible relationships, allowing a more accurate depiction of your IM cost.

Which Counterparties are In-Scope and When

It is a requirement to actively exchange regulatory IM with all in-scope counterparties that exceed the IM threshold can help you prioritize setting up your IM agreements where you anticipate this threshold to be breached sooner rather than later.

How to Redistribute Risk

triBalance can help simplify your OTC derivatives portfolios and reduce funding costs of meeting initial margin obligations. triBalance achieves this through multilateral rebalancing of counterparty risk exposures. The service is available for FX, rates and equity risk classes and can optimize across both bilateral and cleared relationships.

Bringing it All Together with a Seamless IM Solution

With triCalculate IM Analytics providing the insights you need to decide your IM calculation method, identify and prioritize in-scope counterparties and reduce IM funding costs, you can then utilize TriOptima's seamless IM solution to calculate your inputs, manage your margin calls and resolve your disputes.

For more information please email info@trioptima.com or contact your local TriOptima office.

London
+44 20 7382 2200

New York
+1 646 744 0400

Singapore
+65 6372 8181

Stockholm
+46 8 545 25 130

Tokyo
+81 35511 6688

TriOptima (www.trioptima.com) is now part of CME Group.

As the world's leading and most diverse derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex® platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing. With a range of pre- and post-trade products and services underpinning the entire lifecycle of a trade, CME Group also offers optimization and reconciliation services through TriOptima, and trade processing services through Traiana.

All information contained herein ("Information") is for informational purposes only, is confidential and is the intellectual property of CME Group Inc and/or one of its group companies ("CME"). The Information is directed to Equivalent Counterparties and Professional Clients only and is not intended for Non-Professional Clients (as defined in the Swedish Securities Market Law (lag (2007:528) om värdepappersmarknaden)) or equivalent in a relevant jurisdiction. This Information is not, and should not be construed as, an offer or solicitation to sell or buy any product, investment, security or any other financial instrument or to participate in any particular trading strategy. The Information is not to be relied upon and is not warranted, either expressly or by implication, as to completeness, timeliness, accuracy, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed. Access to the Information by anyone other than the intended recipient is unauthorized and any disclosure, copying or redistribution is prohibited without CME's prior written approval. If you receive this information in error, please immediately delete all copies of it and notify the sender. In no circumstances will CME be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. CME and the CME logo are trademarks of the CME Group. TriOptima AB is regulated by the Swedish Financial Supervisory Authority for the reception and transmission of orders in relation to one or more financial instruments. TriOptima AB is registered with the US National Futures Association as an introducing broker. For further regulatory information, please see www.nex.com and www.cmegroup.com.